The diabetes home visitation program

American Journal of Pharmaceutical Education

Volumn 67, Issue 3, 2003, Pages

  Stroup, Jeffrey ^a   Kane, Michael P ^b   Busch, Robert S ^c   Bakst, Gary ^c   Hamilton, Robert A ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Endocrine Group   (United States)

Author keywords

Diabetes; Home visits; Pharmacists

Indexed keywords

EID: 31044440654     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/aj670391     Document Type: Article

References (29)

1. American Diabetes Association. Facts and Figures 1999.
2. ADA. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26: 917-32.
3. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341:1306-9.
4. Reichart P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-9.
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
6. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154:2169-78.
7. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.
8. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM) results of the feasibility study. Diabetes Care. 1995;18:1113-23.
9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
10. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet. 1998;352:854-65.
11. American Diabetes Association. Standards of medical care for patients with diabetes mellitus.Diabetes Care. 2003;26:S33-S50.
12. Baran R, Crumlish K, Patterson H, et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling.Am J Health-Syst Pharm. 1999;56:1535-9.
13. Mechanic D, McApine D, Rosenthal M. Are patients' office visits with physicians getting shorter? N Engl J Med. 2001; 344:198-204.
14. Carmichael J, O'Connell MB, Devine B, et al. Collaborative drug therapy management by pharmacists. Pharmacother. 1997;17:1050-61.
15. Keely J. Pharmacist scope of practice. Ann Intern Med. 2002;136:79-85.
16. World Medical Association Declaration of Helsinki. Accessed at www.wma.net/e/policy/17cnote.pdf.
17. Coast-Senior E, Kromer BA, Kelley C, et al. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636-41.
18. Javor K, Kotsanos J, McDonald R, et al. Diabetic ketoacidosis charges relative to medical charges of adult patients with type I diabetes. Diabetes Care. 1997;20:349-54.
19. Clouse J, Zitter M, Herma M. Heath economic considerations in the management of type 2 diabetes. Managed Care Interface. 2002; 66-71.
20. El-Kebbi IM, Ziemer DC, Gallina D, et al. Diabetes in urban African Americans. Identification of barriers to provider adherence to management protocols. Diabetes Care. 1999;22:1617-20.
21. Mokdad A, Bowman B, Ford E, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
22. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:990-8.
23. Wing R, Blair E, Bononi, et al. Caloric restriction per se is significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care. 1994;17:30-6.
24. Watts NB, Spanheimer RG, Digirolamo M, et al. Prediction of glucose response to weight loss in patients with non-insulin dependent diabetes mellitus. Arch Intern Med. 1990;150:803-6.
25. Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987;147:1749-53.
26. Busch RS, Kane MP. Effect of dexfenfluramine in Syndrome X patients. Obesity Res. 1998;5(Suppl 1):4S.
27. Bakris G. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:2661-7.
28. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-97.
29. Knapp K, Paavola F, Maine L, et al. Availability of primary care providers and pharmacists in the United States. J Am Pharm Assoc. 1999;39:127-35.